NanJing Pharmaceutical Management

Management criteria checks 3/4

NanJing Pharmaceutical's CEO is Liang Zhang, appointed in Apr 2022, has a tenure of 2.08 years. directly owns 0.012% of the company’s shares, worth CN¥777.50K. The average tenure of the management team and the board of directors is 9.8 years and 4.1 years respectively.

Key information

Liang Zhang

Chief executive officer

CN¥1.1m

Total compensation

CEO salary percentage	n/a
CEO tenure	2.1yrs
CEO ownership	0.01%
Management average tenure	9.8yrs
Board average tenure	4.1yrs

Recent management updates

Recent updates

CEO

Liang Zhang (50 yo)

2.1yrs

Tenure

CN¥1,076,300

Compensation

Mr. Liang Zhang is President and Director of NanJing Pharmaceutical Company Limited from April 28, 2022.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Liang Zhang	President & Director	2.1yrs	CN¥1.08m	0.012% CN¥ 777.5k
Jian Sun	Chief Accountant & CFO	12.1yrs	CN¥652.80k	0.012% CN¥ 777.5k
Qing Yang	Chief Auditor & Member of Supervisory Board	no data	CN¥501.30k	no data
Xun Jie Luo	VP & Director	no data	CN¥1.81m	no data
Hong Xiao	Vice President	no data	CN¥266.40k	0.018% CN¥ 1.1m
Yuping Peng	Vice President	no data	CN¥258.30k	0.017% CN¥ 1.1m
Xia Yao	Employee Supervisor & VP	no data	CN¥1.34m	no data
Wen Jun Li	VP & Secretary of the Board of Directors	9.8yrs	CN¥1.82m	0.020% CN¥ 1.3m
Jian Zhong Tang	Vice President	no data	CN¥1.92m	0.020% CN¥ 1.3m

9.8yrs

Average Tenure

51yo

Average Age

Experienced Management: 600713's management team is seasoned and experienced (9.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Liang Zhang	President & Director	2.1yrs	CN¥1.08m	0.012% CN¥ 777.5k
Qing Yang	Chief Auditor & Member of Supervisory Board	12.4yrs	CN¥501.30k	no data
Xun Jie Luo	VP & Director	6.8yrs	CN¥1.81m	no data
Xia Yao	Employee Supervisor & VP	5.2yrs	CN¥1.34m	no data
Jian Jun Zhou	Chairman	9.3yrs	CN¥1.64m	0.028% CN¥ 1.8m
Zhigang Hu	Independent Director	6.1yrs	CN¥95.20k	no data
Yindi Lu	Independent Director	2.1yrs	CN¥71.40k	no data
Jiannan Xu	Director	3.1yrs	CN¥1.48m	0.020% CN¥ 1.3m
Marco Kerschen	Director	2.7yrs	no data	no data
Chunhui Wang	Independent Director	2.1yrs	CN¥71.40k	no data

4.1yrs

Average Tenure

51yo

Average Age

Experienced Board: 600713's board of directors are considered experienced (4.1 years average tenure).

NanJing Pharmaceutical Management

Management criteria checks 3/4

Key information

Recent management updates

NanJing Pharmaceutical Company Limited, Annual General Meeting, May 31, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

NanJing Pharmaceutical Company Limited, Annual General Meeting, May 31, 2024

Full year 2023 earnings released: EPS: CN¥0.45 (vs CN¥0.47 in FY 2022)

NanJing Pharmaceutical Company Limited to Report Q1, 2024 Results on Apr 30, 2024

NanJing Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on Apr 08, 2024

Third quarter 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.11 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.16 in 2Q 2022)

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: CN¥0.47 (vs CN¥0.48 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.12 in 3Q 2021)

Third quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.12 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.12 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.098 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.48 (vs CN¥0.36 in FY 2020)

Third quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.11 in 3Q 2020)

NanJing Pharmaceutical Company Limited announced that it expects to receive CNY 999.999998 million in funding from Nanjing XinGong Investment Group Co., Ltd

Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.093 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.098 (vs CN¥0.073 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.36 (vs CN¥0.33 in FY 2019)

NanJing Pharmaceutical Company Limited to Report Fiscal Year 2020 Results on Mar 27, 2021

New 90-day low: CN¥4.06

New 90-day low: CN¥4.29

Third quarter earnings released

New 90-day low: CN¥4.52

Earnings released

New 90-day high - CN¥5.10

NanJing Pharmaceutical Company Limited to Report First Half, 2020 Results on Aug 22, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age